Figma Shares Indicated To Open $105/$110
On Tuesday, JPMorgan analysts reduced the price target for Gerresheimer AG (BS:GXId) stock to €108 from €122.50, while keeping an Overweight rating. This adjustment follows the company’s recent unexpected profit warning, marking the third such warning in the past two years.
The analysts noted that Gerresheimer’s management attributed the profit shortfall to a slowdown in the oral liquids segment, particularly affecting bottles and closures. This decline was linked to a milder cough and cold season. The analysts speculated that Bormioli, a recent acquisition, might have contributed to the issues, potentially raising questions about the quality of due diligence.
Gerresheimer’s management plans to provide new mid-term guidance with their Q2 results on July 10, followed by a Capital Markets Day later in the summer. The analysts highlighted investor frustration, as the company’s shares fell by 23% on the day of the profit warning.
Despite the current challenges, Gerresheimer’s revenues have increased by €1 billion over the past decade. However, the analysts expressed concern about the company’s EBITDA trajectory and potential equity dilution.
The market reaction reflects ongoing investor concerns, as Gerresheimer’s stock remains at a decade low, with hopes that a third party may intervene to stabilize the situation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.